Patents by Inventor Ming-Hong Xie

Ming-Hong Xie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLEX GENE EDITED CELLS FOR CD70-DIRECTED CANCER IMMUNOTHERAPY
    Publication number: 20230390392
    Abstract: Several embodiments of the methods and compositions disclosed herein relate to immune cells that are engineered to express chimeric antigen receptors (CAR) and/or genetically modified to reduce potential side effects of cellular immunotherapy. Several embodiments relate to genetic modifications to the immune cells, such as Natural Killer (NK) cells, to reduce, substantially, reduce, or eliminate expression of a combination of genes and their corresponding proteins. In several embodiments, one edit is to reduce expression of a marker by the immune cells that would otherwise cause them to be self-targeted by the CAR and at least two additional gene edits to enhance the cytotoxicity and/or persistence of the resulting cells. In several embodiments, the CAR targets CD70, and in some embodiments is used for renal cell carcinoma immunotherapy.
    Type: Application
    Filed: March 6, 2023
    Publication date: December 7, 2023
    Inventors: James Barnaby Trager, Ivan Chan, Chao Guo, Luxuan Guo Buren, Alexandra Leida Liana Lazetic, Mary-Lee Dequéant, Hanspeter Waldner, Changan Guo, Chandirasegaran Massilamany, Ming-Hong Xie, Elizabeth N. Koch, Jacob Usadi, Parin Sripakdeevong
  • METHODS FOR TREATMENT OF CANCER COMPRISING TIGIT-BINDING AGENTS
    Publication number: 20220340653
    Abstract: Methods for enhancing the immune response and/or treatment of diseases such as cancer comprising an agent that specifically binds TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents.
    Type: Application
    Filed: December 9, 2021
    Publication date: October 27, 2022
    Applicant: MEREO BIOPHARMA 5, INC.
    Inventors: Jakob DUPONT, Hema PARMAR, Austin L. Gurney, Ming-Hong Xie
  • TIGIT-binding agents and uses thereof
    Patent number: 10544219
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 28, 2020
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Ming-Hong Xie
  • TIGIT-BINDING AGENTS AND USES THEREOF
    Publication number: 20190077864
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 14, 2019
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: AUSTIN L. GURNEY, Ming-Hong Xie
  • PD-L1-BINDING AGENTS AND USES THEREOF
    Publication number: 20180346571
    Abstract: Agents that specifically bind PD-L1 are disclosed. The PD-L1-binding agents may include polypeptides, antibodies, bispecific agents, homodimeric molecules, and/or heterodimeric molecules. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Application
    Filed: November 16, 2016
    Publication date: December 6, 2018
    Inventors: Austin L. GURNEY, Ming-Hong XIE
  • Tight-binding agents and uses thereof
    Patent number: 10112997
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: October 30, 2018
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. Gurney, Ming-Hong Xie
  • IMMUNOTHERAPY WITH BINDING AGENTS
    Publication number: 20170267758
    Abstract: Binding agents that modulate the immune response are disclosed. The binding agents may include antibodies, soluble receptors, and/or polypeptides. Also disclosed are methods of using the binding agents for the treatment of diseases such as cancer.
    Type: Application
    Filed: May 13, 2015
    Publication date: September 21, 2017
    Applicant: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Austin L. GURNEY, Ming-hong XIE, James Gordon PORTER
  • Immunotherapy with Binding Agents
    Publication number: 20170044268
    Abstract: The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor. In some embodiments, the agents inhibit or suppress the immune response to cancer and/or a tumor. The invention also provides compositions, such as pharmaceutical compositions, comprising the agents. The invention further provides methods of administering the agents so a subject in need thereof. In some embodiments, the invention provides methods of using the agents for cancer immunotherapy. In some embodiments, the invention provides methods of using the agents for treatment of autoimmune diseases.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 16, 2017
    Applicant: ONCOMED PHARMACEUTICALS
    Inventors: Austin L. GURNEY, Ming-Hong XIE, Julie Michelle RODA
  • TIGIT-BINDING AGENTS AND USES THEREOF
    Publication number: 20160376365
    Abstract: Agents that specifically bind TIGIT are disclosed. The TIGIT-binding agents may include polypeptides, antibodies, and/or bispecific agents. Also disclosed are methods of using the agents for enhancing the immune response and/or treatment of diseases such as cancer.
    Type: Application
    Filed: May 27, 2016
    Publication date: December 29, 2016
    Applicant: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Ming-Hong Xie
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20160319034
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 12, 2014
    Publication date: November 3, 2016
    Inventors: Austin L. GURNEY, Ming-Hong XIE, Christopher John BOND
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20160137744
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: September 14, 2015
    Publication date: May 19, 2016
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
  • MET-binding agents and uses thereof
    Patent number: 9168300
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: October 27, 2015
    Assignee: OncoMed Pharmaceuticals, Inc.
    Inventors: Austin L. Gurney, Ming-Hong Xie, Christopher John Bond
  • MET-BINDING AGENTS AND USES THEREOF
    Publication number: 20140286951
    Abstract: The present invention relates to binding agents that specifically bind human MET, binding agents that specifically bind one or more components of the WNT pathway, bispecific agents that bind both human MET and one or more components of the WNT pathway, and methods of using the agents for treating diseases such as cancer.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Inventors: Austin L. GURNEY, Ming-Hong Xie, Christopher John Bond
  • Methods for up-regulating PAP1 in animals suffering from pancreatic disorders
    Patent number: 8178082
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: December 14, 2010
    Date of Patent: May 15, 2012
    Assignee: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • Interleukin-22 Polypeptides, Nucleic Acids Encoding The Same And Methods For The Treatment Of Pancreatic Disorders
    Publication number: 20110091417
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: December 14, 2010
    Publication date: April 21, 2011
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS
    Publication number: 20090130107
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: September 24, 2008
    Publication date: May 21, 2009
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
    Publication number: 20090093057
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: May 31, 2007
    Publication date: April 9, 2009
    Applicant: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
    Patent number: 7445905
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: November 4, 2008
    Assignee: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood
  • INTERLEUKIN-22 POLYPEPTIDES, NUCLEIC ACIDS ENCODING THE SAME AND METHODS FOR THE TREATMENT OF PANCREATIC DISORDERS
    Publication number: 20070160612
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Application
    Filed: January 26, 2007
    Publication date: July 12, 2007
    Applicant: Genentech, Inc.
    Inventors: Austin Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen Maruoka, Jessica Foster, Audrey Goddard, William Wood
  • Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
    Patent number: 7226591
    Abstract: The present invention is directed to interleukin-22 polypeptides and nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention.
    Type: Grant
    Filed: September 10, 2002
    Date of Patent: June 5, 2007
    Assignee: Genentech, Inc.
    Inventors: Austin L. Gurney, Sudeepta Aggarwal, Ming-Hong Xie, Ellen M. Maruoka, Jessica S. Foster, Audrey Goddard, William I. Wood